Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Core Insights - Allogene Therapeutics has achieved a favorable arbitration outcome with Servier regarding cemacabtagene ansegedleucel (cema-cel), reaffirming its full development and commercial control in the U.S., EU, and UK, while paving the way for global commercialization rights [1][5][8] Group 1: Arbitration Outcome - The tribunal rejected Cellectis's allegations against Servier regarding development obligations and financial claims, determining that milestone payments are contingent upon FDA acceptance of a Biologics License Application (BLA) [6] - A partial termination of the license was ordered, limited to the UCART19 V1 product, and Cellectis was directed to negotiate a direct license to Allogene on similar terms if pursued [6] Group 2: Future Developments - With the legal matter resolved, Allogene is entering 2026 with improved fundamentals and is approaching a significant catalyst period in the allogeneic CAR T field [2] - An interim futility analysis for cema-cel in first-line patients with large B-cell lymphoma (LBCL) is scheduled for the first half of 2026 [2][5] Group 3: Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming to provide readily available cell therapy on demand [3] - The company is led by a management team with extensive experience in cell therapy and is developing a pipeline of "off-the-shelf" CAR T cell product candidates [3]